Vertex Pharmaceuticals (VRTX) Other Operating Expenses (2009 - 2026)
Vertex Pharmaceuticals (VRTX) posted quarterly Other Operating Expenses of $393.5 million for Q1 2026, down 48.49% year-over-year from $764.0 million in Q1 2025, and down 24.82% quarter-over-quarter from $523.4 million in Q4 2025.
Vertex Pharmaceuticals (VRTX) Other Operating Expenses (2009 - 2026) Analysis & Trends
Vertex Pharmaceuticals' Other Operating Expenses history runs 18 years deep, the most recent figure standing at $393.5 million for Q1 2026.
- In Q1 2026, Other Operating Expenses fell 48.49% year-over-year to $393.5 million; the TTM figure through Mar 2026 stood at $1.8 billion (down 72.4% YoY), while the FY2025 annual figure was $2.2 billion, down 64.84% from the prior year.
- Other Operating Expenses for Q1 2026 stood at $393.5 million, down from $523.4 million in the prior quarter.
- The five-year high for Other Operating Expenses was $4.8 billion in Q2 2024, with the low at $240.3 million in Q1 2022.
- The 5-year median for Other Operating Expenses is $410.6 million (2025), against an average of $682.0 million.
- The sharpest annual moves came in 2024 and 2025: Other Operating Expenses surged 1052.09% in 2024, then tumbled 91.48% in 2025.
- Vertex Pharmaceuticals' Other Operating Expenses stood at $307.7 million in 2022, then grew by 9.03% to $335.5 million in 2023, then surged by 51.92% to $509.7 million in 2024, then grew by 2.69% to $523.4 million in 2025, then decreased by 24.82% to $393.5 million in 2026.
- Business Quant data shows VRTX's Other Operating Expenses at $393.5 million in Q1 2026, $523.4 million in Q4 2025, and $467.4 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Roivant Sciences | 26.16 Bn | 26.85 Bn | 1.16 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 511.00 Mn |
| Mar 31, 2026 | 393.50 Mn |
| Dec 31, 2025 | 523.40 Mn |
| Sep 30, 2025 | 467.40 Mn |
| Jun 30, 2025 | 410.60 Mn |
| Mar 31, 2025 | 764.00 Mn |
| Dec 31, 2024 | 509.70 Mn |
| Sep 30, 2024 | 407.90 Mn |
| Jun 30, 2024 | 4.82 Bn |
| Mar 31, 2024 | 419.30 Mn |
| Dec 31, 2023 | 335.50 Mn |
| Sep 30, 2023 | 371.60 Mn |
| Jun 30, 2023 | 418.50 Mn |
| Mar 31, 2023 | 612.10 Mn |
| Dec 31, 2022 | 307.70 Mn |
| Sep 30, 2022 | 315.80 Mn |
| Jun 30, 2022 | 274.50 Mn |
| Mar 31, 2022 | 240.30 Mn |
| Dec 31, 2021 | 371.90 Mn |
| Sep 30, 2021 | 264.40 Mn |